WO1983004255A1 - Reporter compounds - Google Patents
Reporter compounds Download PDFInfo
- Publication number
- WO1983004255A1 WO1983004255A1 PCT/US1982/000725 US8200725W WO8304255A1 WO 1983004255 A1 WO1983004255 A1 WO 1983004255A1 US 8200725 W US8200725 W US 8200725W WO 8304255 A1 WO8304255 A1 WO 8304255A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- fluorophore
- water
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 246
- 125000006853 reporter group Chemical group 0.000 claims abstract description 50
- 125000005620 boronic acid group Chemical class 0.000 claims abstract description 40
- 230000003381 solubilizing effect Effects 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 25
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 22
- 125000002524 organometallic group Chemical group 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 17
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 61
- 238000010186 staining Methods 0.000 claims description 38
- 150000002978 peroxides Chemical class 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 21
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 20
- 239000004744 fabric Substances 0.000 claims description 20
- 102000007562 Serum Albumin Human genes 0.000 claims description 18
- 108010071390 Serum Albumin Proteins 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 210000003743 erythrocyte Anatomy 0.000 claims description 16
- 230000002209 hydrophobic effect Effects 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 230000000536 complexating effect Effects 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- -1 polyethylene Polymers 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- 239000000376 reactant Substances 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 7
- 238000005282 brightening Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229910052796 boron Inorganic materials 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000010668 complexation reaction Methods 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 239000008279 sol Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 229960002036 phenytoin Drugs 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 108010036302 hemoglobin AS Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 description 25
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 15
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- JORMZLCKCZMVJM-UHFFFAOYSA-N 4'-(4-fluorophenyl)acetanilide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC=C(F)C=C1 JORMZLCKCZMVJM-UHFFFAOYSA-N 0.000 description 10
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- 0 **B1*C(*)(*)C(*)(*)C(*)*1 Chemical compound **B1*C(*)(*)C(*)(*)C(*)*1 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000007998 bicine buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000003136 vital staining of cell Methods 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XMVGYYBQCXVVHU-UHFFFAOYSA-N (3-aminophenyl)boronic acid;sulfuric acid Chemical compound OS(O)(=O)=O.NC1=CC=CC(B(O)O)=C1 XMVGYYBQCXVVHU-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- DBVFWZMQJQMJCB-UHFFFAOYSA-N 3-boronobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1 DBVFWZMQJQMJCB-UHFFFAOYSA-N 0.000 description 1
- LCPDRGMZQSQOCQ-UHFFFAOYSA-N 4-boronobenzenesulfonic acid Chemical compound OB(O)C1=CC=C(S(O)(=O)=O)C=C1 LCPDRGMZQSQOCQ-UHFFFAOYSA-N 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- IDBRDXGJPFCEFF-QMMMGPOBSA-N N,N-dihydroxy-L-phenylalanine Chemical compound ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 IDBRDXGJPFCEFF-QMMMGPOBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- LUPAACXLIDTMOT-UHFFFAOYSA-N [3-(diaminomethylideneamino)phenyl]boronic acid Chemical compound NC(=N)NC1=CC=CC(B(O)O)=C1 LUPAACXLIDTMOT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 125000006854 dansyl reporter group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K9/00—Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy
- C09K9/02—Organic tenebrescent materials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
Definitions
- Such molecules be capable of being transferred from one phase to another; e.g., from an aqueous to a non-aqueous phase, or across biological membranes.
- the invention features a new class of reagents which we have named the Boronate-Dependent Phase Transfer (BorAdept) compounds.
- the new compounds allow groups which can 1) report on conditions within living cells and tissues or 2) modify metabolic parameters within living tissues to be presented to and taken up by cells under non-toxic conditions.
- the new compounds have one of two general formulae:
- each X and Y independently, is N, O, or S, and r represents a receptor group which, with X and Y, forms adducts or complexes with boronic acids.
- Cg 1 and Cg 2 are carrier groups which each include a solubilizing group which is substantially ionizable in water
- Rp 1 and Rp 2 are groups which each include a reporter group which is a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group.
- the new compounds because of their water-solubility at or near physiological pH, provide reporter groups with greatly enhanced versatility.
- formula (1) and (2) compounds to exist in pH-dependent equilibria with their dissociated forms renders them useful for a broad range of applications.
- Many of these compounds have the additional advantage provided by the boronic acid-derived portion of the molecule which, when dissociated from the remainder of the molecule, can exhibit the selective affinity which boronic acids have for organic compounds having reactive hydroxyl, amino, and thiol groups, the aforesaid equilibria also allow some reporter groups to enter environments where their properties are advantageously altered. For example, some of the fluorescent reporter groups, under certain conditions, can be brought into contact with hydrophobic pockets in cells or organic phases where they exhibit enhanced or quenched fluorescence.
- aspects of the invention feature applications of the new compounds such as the staining of living cells, proteins, and fabrics, and various assay methods.
- the invention also features new boronic acid containing compounds, which are useful both by themselves, and as starting materials for BorAdept compounds.
- Figure 1 is a flow chart diagramming an assay method of the invention.
- Figure 2 is a perspective view of apparatus for carrying out one of said methods.
- the compounds represented in formula (1) and (2) each is a reaction product between a compound which includes a boronic acid, and a compound which includes a receptor group (r) which, with X and Y, forms adducts or complexes with boronic acids.
- one of the compounds also includes a group (Rp 1 or Rp 2 ) which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group.
- the other compound includes a carrier group (Cg 1 or Cg 2 ) which includes a strongly basic or acidic solubilizing group which is substantially ionizable in water.
- Rp 1 is bonded to boronic acid in formula (1)
- Rp 2 is bonded to the receptor in formula (2).
- Cg 1 is bonded to the receptor in formula (1), while Cg 2 is bonded to boronic acid in formula (2).
- the compounds of formula (1) are generally made by the reaction
- the compounds of formula (2) are generally made by the reaction
- the compounds of formula (1) and (2) can, if desired, contain more than one reporter group, and in such case the properties of the additional group or groups can influence the dynamic equilibrium of the compound.
- each R 2 - R 7 is hydrogen, aryl, alkyl, heteroalkyl, hetroaryl, aralkyl, or a solubilizing group which is substantially ionized in water, provided that the compound contains at least one such solubilizing group.
- n and m independently, is 0, 2, or 3, provided that both cannot be 0.
- each R 2 - R 5 can be different in successive repeating units. For example, where n is 2, the R 2 attached to the first carbon atom can be hydrogen, while the R 2 attached to the second carbon atom is a solubilizing group.
- each of groups R 2 - R 7 preferably contains between 0 and about 12 carbon atoms.
- the solubilizing group is preferably a sulfonic acid, a carboxylic acid, quaternary ammonium, a guanidinium group, or a phosphate group.
- the first step in making a formula (1) compound is to make the desired ReportaBora. This can be done by reacting a desired organic boronic acid with the desired Rp 1 . Alternatively, the desired Rp 1 precursor can undergo hydroboration with catechol boirane, or can participate in a
- the reporter group can first be incorporated into a compound having a desired property, e.g., good electron withdrawing power for enhanced activation of the boronate.
- Table I shows the structures of some ReportaBora compounds which provide the Rp 1 -B portion of the compounds of formula (1) . Each of these can react with any CarrierCeptor, as defined above, to produce a formula (1) compound.
- Table I also indicates the utility of the reporter group of each listed ReportaBora. This utility, along with other factors, including choice of CarrierCeptor, allows the choice of starting materials which will react to produce a formula (1) compound possessing the properties required for a given application.
- Table II shows the structures and some properties of some preferred CarrierCeptor
- CarrierCeptors can be reacted with any ReportaBora, such as those listed in Table I, to make a compound of the general formula (1).
- Cg 2 typically includes both a solubilizing group and an organic group linking the solubilizing group to the boron atom.
- Formula (2) compounds thus typically have one of the following general formulae:
- Sol is the aforementioned strongly basic or acidic solubilizing group and A 1 is alkyl, aryl, heteroaryl, heteroalkyl, or aralkyl; most preferably A 1 contains between 3 and about 12 carbon atoms.
- a 2 - A 7 independently, is hydrogen, aryl, alkyl, hetoralkyl, heteroaryl, aralkyl, or Rp 2 , the group containing a reporter group, provided that the compound contains at least one Rp 2 .
- Each of A 2 - A 7 , except Rp 2 preferably contains between 0 and about 12 carbon atoms.
- each of p and q is 0, 2, or 3, provided that both cannot be 0.
- each A 2 - A 4 can be different in successive repeating units.
- the A 2 attached to the first carbon atom can be hydrogen, while the A 2 attached to the second carbon atom can be Rp 2 .
- the first step in making a formula (2) compound is to make the desired ReporterCeptor by
- Rp 2 can consist entirely of the desired reporter group, or the reporter group can be incorporated into an Rp 2 having a desired property; e.g., good
- solubilizing groups are suitable compounds.
- CarrierBoras (putting aside considerations such as cost) in having a wide variety of CarrierBoras to choose from, and one or a few can be reacted with a wide variety of ReporterCeptors.
- An example of one such versatile CarrierBora is the compound shown below which, although not commercially available, can be made using conventional methods.
- Compound (11) is particularly useful because its boronate group is highly reactive as a result of the strong electron withdrawing action of the sulfonephenyl group
- CarrierBoras are m-carboxyphenyl boronic acid, p-sulfophenylboronic acid, m-guanidinophenyl boronic acid, and p-trimethylammoniumphenyl boronic acid. The first two are negatively charged, while the latter two are positively charged.
- Compound 12 is made by reacting m-aminophenyl boronic acid, in aqueous ethanol at pH 8.0, with
- a formula (2) compound is typically made by dissolving the desired ReporterCeptor in anorganic, water-miscible solvent, e.g., dimethyl acetamide, acetone, or dimethyl formamide, and then adding an excess of the desired CarrierBora in water or an appropriate aqueous buffer.
- anorganic, water-miscible solvent e.g., dimethyl acetamide, acetone, or dimethyl formamide.
- Both formula (1) and formula (2) compounds can, if desired, contain more than one reporter group.
- a group, Rp 3 including a second reporter group can be attached at any suitable reactive site on formula (1) or (2) compounds, but will most often be attached at a site on Rp 1 or Rp 2 so that the ReportaBora or ReporterCeptor, dissociated from the carrier part of the molecule, bears both reporter groups.
- Compound 3 of Table III an example of such a compound, bears two staining reporter groups.
- the compounds of both formulae (1) and (2) in which the reporter group is a chromophore, an antigen, an organometallic group, an isotopically-labelled group, or a fluorophore are useful for staining living cells, proteins, and other materials such as fabrics and paper products.
- formula (1) compounds in aqueous solution at pH values around physiological pH, exist in dynamic equilibria with their starting materials.
- the equilibrium permits the presentation of the ReportaBora to cells in media compatible with living cells, and uptake by cell membranes without toxicity.
- the diagram below illustrates the mechanism of uptake of ReportaBora by cells.
- the scheme is general, and is not strictly applicable to all formula (1) compounds.
- a formula (1) compound having a positively-charged solubilizing group such as quaternary ammonium is more likely to enter the cell intact rather than operating as shown below.
- many ReportaBoras do not exhibit altered reporting properties inside cells.
- the equation (3) equilibrium permits hydrophobic pockets of the cell membrane to selectively extract ReportaBora, which then enters the cell.
- the ReportaBora carried by lipophillic components of the cell, is capable of selectively staining cellular components.
- the boronic acid portion of the molecule binds selectively to certain biological groups within cells which contain appropriately distributed hydroxyl, amino, and thiol groups; binding is particularly favored when such groups are in non-aqueous regions of the cell.
- Certain complex lipids, mucopolysaccharides, liposaccharides, glycoproteins, and proteins contain such reactive groups.
- formula (1) compounds make them useful as vital cellular stains in the diagnosis of certain disease states, including certain genetic disorders, particularly those which cause mucopolysaccharidosis, liposaccharidosis, or an increase in either the number or size of cellular lysosomal components.
- Hurler's Syndrome, Hunter's Syndrome, and ⁇ -glucuronidase deficiency can be diagnosed by culturing a patient's cells, staining them with a fluorescent formula (1) stain, e.g., compound 1 of Table III, and then examining them using a fluorescent microscope.
- the vital staining patterns and the rate of destaining of certain cellular particulates can provide valuable diagnostic information.
- the compounds are also useful for gaging the viability and motility of human and animal sperm.
- the selectivity of formula (1) compounds also makes them useful in comparing staining patterns of various cells in different cell cycle stages.
- the stains can also be useful for staining catecholamine-rich regions of cells; for example, the compounds stain epinephrine, norepinephrine, dopamine, di-hydroxyphenylalanine, and 3, 4-hydroxphenylacetic acid, compounds which are abundant in nervous and adrenal tissue and are thus useful for the diagnosis of a variety of clinical conditions.
- Staining of cells can be carried out using any most conventional vital staining techniques, but is preferably carried out according to either of the following two preferred processes.
- cells to be stained are grown on a coverslip, the culture medium is poured off, the cells are washed with physiological buffer several times, and the coverslip is covered for 5 minutes with a formula (1) compound dissolved in physiological buffer. The coverslip is then washed, turned over onto a slide, and examined using a light or fluorescent microscope, or processed further, e.g., tested for the presence of immune complexes, radioactive label, or heavy metals.
- ReportaBora is added directly to the cell culture medium in which CarrierCeptor is already present as the buffer. After the desired degree of staining is complete, the medium is poured off and the cells are examined.
- An additional step may be added to either preferred staining method to obtain additional information, such as the relative dynamic stability of the bonds between the stain and various cellular components.
- cells are transferred to fresh culture medium and monitored to determine the relative rates at which the stain leaches out of various cellular components.
- the formula (1) compound contains an organometallic electron opaque reporter group, following vital staining, the cells are fixed and prepared for examination with an electron microscope.
- any formula (1) compounds can be used for vital staining, some are more useful than others for certain applications.
- One factor affecting choice of dye is the strength of the bond between the ReportaBora and the CarrierCeptor; very tight complexes, such as those formed with strong CarrierCeptors such as TAPSO, and with certain
- ReportaBoras containing strong Lewis acid boronic acids tend to make it more difficult for cell membranes to extract appreciable amounts of the ReportaBora. For this reason, it is sometimes preferable, for vital staining, to use a formula (1) stain made with a weaker complexing CarrierCeptor such as TES or MOPSO (Table II). Because Carrier Ceptors which form weak complexes with boronic acids also tend to be less reactive with boronic acids, when it is desired to make a formula (1) compound using a weak CarrierCeptor such as MOPSO, it is often desirable to employ a more reactive ReportaBora; i.e., one in which the boron atom is more electron deficient. Such a reactive ReportaBora is one in which Rp contains a linking group, proximate to the boron atom, which has strong electron withdrawing power. Referring to Table I, FBIII contains the linking group
- ReportaBoras e.g., FluoraBora I, containing groups such as the sulfamido linkage, which do not exert strong electron withdrawing action, complex to a lesser extent with weakly complexing CarrierCeptors, and formula (1) compounds wherein the ReportaBora is FluoraBora I are thus preferably made with a strong CarrierCeptor such as TAPSO.
- fluorescent stain for a particular application is whether the fluorophore is enhanced or quenched (inhibited) in hydrophobic environments such as the hydrophobic protein pockets which the ReportaBora is likely to seek within a cell. Still another consideration is whether the fluorophore exhibits a shift in emission wavelength in such an environment; both enhancement and emission shift can advantageously increase detectability of dyes within cells.
- Formula (2) dyes can also be used for the vital staining of cells.
- the diagram below illustrates the mechanism of uptake of ReporterCeptor by cells.
- Formula (2) dyes can also be used for the vital staining of cells.
- the diagram below illustrates the mechanism of uptake of ReporterCeptor by cells.
- formula (1) compounds there are exceptions to this general scheme.
- Cells are contacted with an aqueous solution of the stain, which is in dynamic equilibrium with its respective CarrierBora and ReporterCeptor.
- the cell selectively extracts ReporterCeptor molecules, which enter and stain the cells, and can exhibit altered reporting properties such as fluorescence enhancement or wavelength shift in hydrophobic regions of the cell.
- those of formula (2) stains are not boronic acids, and do not form such complexes with particular cellular components; their specificity depends instead on the nature of the receptor portion of the molecule.
- Formula (2) stains in which the solubilizing group is a positively charged group; e.g., quaternary ammonium, can also be used for vital cell staining.
- the entire compound may enter the cell and establish local hydrophobicity- dependent equilibria within the cell.
- a further refinement to vital cell staining using formula (1) and (2) compounds is to employ a stain having more than one staining reporter group.
- a formula (1) stain can have the structure where Rp 1 and Rp 3 each is a group which includes a fluorophore, chromophore, an antigen, an isotopically-labelled group, or an organometallic compound.
- Compound 12 of Table I, complexed with TAPSO (Table II) is an example of such a compound, bearing a fluorophore which provides cellular information at the level of the fluorescent microscope, and an electron-opaque organometallic group which provides information on the electron microscope level; the fluorescence pattern of a stained cell indicates to the electron microscopist that that cell took up stain, indicates which portions of the cell were stained at the level of resolution of the light microscope, and, after preparation for electron microscopy, allows a comparison of staining patterns within the same cell at the light and ultrastructural levels.
- the formula (1) stains can also be used to permanently stain proteins.
- the preferred method for carrying out such staining is to react the protein to be stained with the dye under mild conditions; e.g., at room temperature or lower, at pH 4 to 10, in the absence of an organic solvent. Excess ReportaBora can then be removed by carrying out dialysis against the CarrierCeptor used to make the stain.
- compound 9 Table III
- CBII highly water-insoluble ChromaBora II
- Table I highly water-insoluble ChromaBora II
- Serum albumin is then added and the mixture then dialyzed against TAPSO to remove excess CBII.
- CBII enters the hydrophobic pockets of serum albumin, leaving its CarrierCeptor, TAPSO, in the aqueous phase.
- Dialysis against TAPSO removes excess CBII as the formula (1) complex, but is unable to remove CBII from the hydrophobic pockets of the serum albumin, which is thus permanently stained.
- Formula (1) and (2) compounds can also be used to stain or brighten a variety of other materials such as fabrics and paper products.
- Staining is carried out by simply contacting the material to be stained with an aqueous solution of the desired formula (1) or (2) compound (generally a colored or a fluorescent compound) until the desired degree of staining has been achieved.
- Brightening of fabrics is carried out using a fluorescent formula (1) or (2) compound, and can often be performed in a conventional clothes washing machine, in soapy or clean water.
- Many fabrics can be brightened using the new compounds, including cellulose-containing fabrics, such as cotton and linen, and nitrogen-containing fabrics such as wool and silk, and various synthetics.
- formula (1) compounds because the FluoraBora of the equation (3) equilibrium is attracted to the hydroxyl groups of the fabric.
- formula (1) dyes are also preferred, and the brightening process may include an additional step. Following the step of contacting the fabric with the fluorescent formula (1) compound, the fabric is contacted with an oxidizing agent such as peroxide, which breaks the carbon-boron bond of the formula (1) compound, releasing Rp 1 - OH, which is then. better locked into the hydrophobic pockets in the fabric. Even greater brightening can be obtained by employing a formula (1) compound in which the fluorescent part of the molecule exhibits enhanced fluorescence in hydrophobic environments.
- a colored or fluorescent formula (1) compound can be used to measure, in aqueous solution, an unknown amount of a compound which participates in an enzymatic procedure ("procedure", as used herein, includes one or a series of reactions) in which an enzyme acts on a substrate, or a chemical procedure which results in the production of peroxide.
- peroxide assay excesses of all of the reactants participating in the procedure are introduced into a reaction zone, e.g., a test tube, along with the sample containing an unknown amount of the compound to be assayed. The peroxide produced is brought into contact with a known amount of the formula (1) compound.
- the peroxide an oxidizing agent, breaks the carbon-boron bond of the ChromoBora or FluoroBora, releasing Rp 1 - OH, which is then contacted with a substance having a greater affinity for Rp 1 - OH than for the formula (1) compound.
- the fluorescence or color intensity of the substance is then measured as a measure of the unknown amount of the compound being assayed.
- the selective affinity substance can be a water-immiscible organic solvent which is capable of extracting Rp 1 - OH away from the formula (1) compound.
- the solvent forms a fluorescent organic layer separate from the aqueous layer; if desired the two layers can then be separated to facilitate quantification of the fluorescence of the organic layer.
- Table V shows the extent to which three FluoraBoras, complexed with six CarrierCeptors in aqueous solution, are extracted into ethyl acetate.
- those made with comparatively tightly-complexing TAPSO are most preferred for the peroxide assay because, absent peroxide (i.e., in a blank reaction), a comparatively large proportion of the fluorescence remains in aqueous solution, unextracted by ethyl acetate.
- the reporter group of the formula (1) compound is a fluorophore
- the manner in which the organic solvent being used affects the properties of the fluorophore is the manner in which the organic solvent being used affects the properties of the fluorophore.
- Some fluorophores are enhanced, i.e., their fluorescence is made more intense, in a given organic solvent, while others exhibit diminished fluorescence (quenching).
- Some fluorophores may also exhibit altered emission spectra in certain organic solvents.
- any fluorescent formula (1) compound can be used, provided its fluorophore is not totally quenched in the organic solvent, both enhancement and spectrum alteration desirably heighten detectability.
- Table VI shows the relative fluorescence of three FluoraBoras combined with TAPSO, compared to the fluorescence of equal concentrations of FluoraBora in the water-immiscible organic solvent ethyl acetate. Because FBPA and FBI are enhanced (two and seven-fold, respectively), formula (1) compounds made with them are suitable for use in the peroxide assay described above. FBIII, on the other hand, is quenched to a large extent in ethyl acetate, and formula (1) compounds made with it are therefore not desirable for use in the assay in which ethyl acetate is employed.
- the selective affinity substance in the peroxide assay can be a water-miscible protein which has a greater affinity for Rp 1 than for the corresponding formula (1) compound being used.
- Preferred proteins are those, e.g., serum albumin, which posses hydrophobic pockets which can attract Rp 1 .
- the formula (1) compound be fluorescent, and that the protein be capable of producing an observable effect, preferably enhancement or, less preferably, quenching, of fluorescence, of Rp 1 , there being no easily observed water/protein phase separation.
- Table VII shows the relative enhancement or inhibition with serum albumin, of the three fluorophores of eighteen formula (1) compounds. Table VII shows that, in general, FBI and, to a lesser extent, FBPA, are enhanced in serum albumin, while FBIII exhibits diminished fluorescence.
- each of the three fluorophores of Table VII is enhanced or inhibited depends, to a significant extent, on the CarrierCeptor with which it is combined.
- enhancement, in serum albumin, of FBPA and FBI, and inhibition of FBIII is much greater if the formula (1) compound has been made with loosely complexing MOPSO than with tightly complexing TAPSO. This is because the loose Rp 1 -MOPSO complex favors an equilibrium in which more free Rp 1 is available to seek the hydrophobic pockets of serum albumin, where enhancement or inhibition of fluorescence occurs.
- a blank should always be run in which the peroxide-generating reagents are not added, so that enhancement or inhibition in the absence and presence of those reagents can be compared.
- the other observable effect which a water-miscible protein such as serum albumin can have on a fluorophore is a shift in the peak emission spectrum; such a shift can, as in the case of a water-immiscible organic solvent, aid detectability.
- FBPA for example, normally emits at 460 nm, while its dissociated fluorophore, in the hydrophobic pockets of serum albumin, emits at 427 nm.
- Glucose is an example of a compound which can be measured using the above-described method.
- a sample containing an unknown amount of glucose is placed in a test tube with a known amount of Compound 1 (Table III) and a known amount of serum albumin in aqueous solution at pH between 8 and 9.
- An excess of glucose oxidase is then added, and the increse in fluorescence compared to that of a no-enzyme, no-substrate blank is measured as a measure of the amount of peroxide produced, which in turn is a measure of the amount of glucose in the sample.
- glucose oxidase catalyzes the oxidation of glucose to gluconic acid by oxygen, forming H 2 O 2 .
- the H 2 O 2 oxidizes the C-B bond of FBI in the formula (1) complex, forming dansylamido phenol, which enters the serum albumin pockets, where it exhibits enhanced fluorescence.
- certain formula (1) compounds can also be used to measure an unknown amount of a compound which participates in an enzymatic procedure in which an enzyme acts on a substrate.
- the method employs fluorescent formula (1) compounds in which Rp, includes a group, positioned between the boron atom and the fluorophore, capable of acting as a substrate for the enzyme.
- a desired enzyme substrate can be incorporated into a desired formula (1) compound using coventional techniques.
- the formula (1) compound being used is introduced into a reaction zone, along with excesses of all of the other participating reactants except the compound to be measured, and a sample containing the compound to be measured.
- the enzymatic reaction releases modified fluorophore which, after completion of the reaction, is contacted with a water-immiscible organic solvent or a water-miscible protein, as described above for the peroxide assay.
- the extent of fluorophore extraction or fluorescence enhancement or inhibition is then measured versus a blank, as described above, as a measure of the unknown compound. If a water-miscible protein is used, the rate of the enzymatic reaction can also be followed by measuring the rate at which fluorescence enhancement increases.
- Esterases such as Upases are examples of compounds which can be assayed using this method.
- a test tube in aqueous solution, is placed a known amount of compound 6 (Table III), of the formula
- a sample containing an unknown amount of lipase is then added. Lipase present in the sample breaks the ester bond (as indicated by the dotted line), releasing modified Rp 1 , containing the fluorescent dansyl group, which is then extracted or contacted with a known amount of serum albumin and fluorescence measured, as described above for the peroxide assay.
- Antibody Assay Another new assay employing formula (1) compounds is an antibody assay employing red blood cells. (Red Blood cells are commonly used in other antibody assays.) A formula (1) compound is used in which the reporter group of Rp 1 is a hapten capable of complexing with the antibody being assayed.
- Red blood cells are contacted, in aqueous solution, with the formula (1) compound, which is in an equation (3)-type equilibrium with its starting materials.
- the red blood cell membrane selectively extracts hapten-containing ReportaBora, thus becoming sensitized.
- the sensitized red blood cells are contacted with a sample containing an unknown amount of antibody, together with complement which is capable of participating in the complexation of the hapten with the antibody.
- the antibody in the sample complexes with the hapten in the sensitized cell membrane, fixing complement and causing cell lysis and the release of hemoglobin from the cell.
- the amount of hemoglobin released is a measure of the amount of antibody in the sample.
- the formula (1) compound used contains two reporter groups; a hapten and a fluorophore, both of which become incorporated into the membranes of sensitized red cell ghosts by the BorAdept process.
- the ghosts are contacted with antibody and complement, lysis of the ghost stroma occurs, causing the release of soluble fragments containing fluorophore.
- the solution can contain a CarrierCeptor to facilitate solubilization of the fluorescent fragments. The fluorescence in solution is then measured as a measure of the antibody titer. Solubilization of Therapeutic Agents
- the BorAdept system of the invention can greatly facilitate the administration of therapeutic agents such as drugs which have heretofor been difficult to administer because of poor water solubility or difficult to test in cell culture systems.
- a desired therapeutic agent can be incorporated into either a formula (1) or (2) compound. In either case, by virtue of the equation (3) or (4) equilibrium, the agent is not only solubilized, but is in a form which enables the agent to be presented to and taken up by cells to which it is desired to deliver the agent, by the same mechanism by which fluorophore reporter groups are taken up by cells to be stained.
- Therapeutic formula (1) compounds are generally made in the same way fluorescent formula (1) compounds are made; i.e., the de-sired therapeutic agent or a suitable precursor or derivative thereof is first reacted with the desired boronic acid to form a ReportaBora (in this case, a TheraBora), which is then reacted with the desired CarrierCeptor.
- the boronic acid is preferably chosen to include a group which renders the boronic acid reactive with the therapeutic agent being used.
- Compound 4 of Table III is an example of a formula (1) compound containing a derivative of therapeutic agent, the water-insoluble anti convulsant diphenyl hydantoin.
- Another example is compound 2 of Table III, containing a derivative of the water-soluble anti-epileptic drug carbamazepine. This new compound is made according to the reaction scheme illustrated on the following page.
- Therapeutic formula (2) compounds are generally made in the same way that fluorescent formula (2) compounds are made, i.e., the desired therapeutic agent or a suitable precursor or derivative thereof is, if necessary, incorporated into a compound having a desired property to make Rp 2 , which is then reacted with a compound of the
- Compound 5 of Table IV is made according to the reaction scheme illustrated on the following pages:
- Table I lists some preferred ReportaBoras of the invention. These new compounds, as is discussed above, are useful in making formula (1) BorAdept compounds. In addition, we have discovered that they have many applications by themselves, even when not complexed with a CarrierCeptor in a formula (1) compound. Many of these applications, e.g., the peroxide assay, are similar in principle to applications of formula (1) compounds.
- the ReportaBoras of the invention are generally made by reacting a desired reporter group-containing compound (Rp 4 ) with a desired organic boronic acid capable of reacting with that
- organic boronic acid has the general formula
- R o is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl
- Z is a group capable of chemically combining with the Rp 4 being used.
- R o contains between 3 and about 25 carbon atoms.
- a preferred (because of ready availability) boronic acid is m-aminophenyl boronic acid, in which Z is
- Rp 4 usually has the formula where Re is the reporter group and Y is a group capable of chemically combining with the Z portion of the boronic acid being used.
- the ReportaBoras made by reacting the aforesaid boronic acids and Rp 4 's thus either have the formula
- Z is NH 2 , OH, SH, or COOH, and in some preferred
- X being any halogen.
- the carbon or sulfur atom of Y to which X was bonded bonds to Z replacing an H.
- Z' is thus Z minus an H
- Y' is Y minus X. (there is no Y' when Y consists entirely of X).
- the resulting ReportaBoras have the formula.
- FBPA ReportaBoras
- the first step in our synthesis of FBPA is to make the sulfonyl chloride of Ilford's compound by reacting it with PCl 5 .
- the new sulfonyl chloride has the formula:
- the new compound has a chemically stable crystalline structure with a melting point of 119°C. Besides being useful for making ReportaBoras, it is, also useful as a fluorescent reporter for labelling proteins such as antibodies and other compounds such as amino acids and polyamines. Because of its azuxe fluorescence, it can be used in conjunction with red and yellow fluorescent dyes in immunofluorescent labelling experiments.
- Compound 21 is a diaryl sulfonyl chloride, and is one of a family of fluorescent compounds which we refer to as DARPSYL chlorides. These compounds are the sulfonyl chloride derivatives of compounds of the general formula
- Ar 1 or Ar 2 is an aromatic group containing a sulfonyl chloride group and Q is hydrogen or an alkyl group.
- the compounds in which Ar 1 contains the sulfonyl chloride group are the "A” compounds, and are derived from the DARPSYL compounds described in British Pat. No. 670,857.
- the sulfonyl chloride derivatives in which Ar 2 contains a sulfonyl chloride group are the "B” compounds, and are also useful fluorescent stains.
- the new A-DARPSYL chloride, (compound 21), as well as other DARPSYL-chlorides, can be combined with organic boronic acids to make useful FluoraBoras.
- FBPA (Table I)
- A-DARPSYL chloride described above is combined with m-aminophenyl boronic acid in DMF-H 2 O.
- the mixture is then acidified, water is added causing FBPA to precipitate out and recrystallization is carried out, from cyclohexane.
- Another FluoraBora listed in Table I, FBI is made by adding an acetone solution of dansyl chloride to an aqueous acetone solution of m-aminophenyl boronic acid hemisulfate containing 2.5 equivalents of sodium bicarbonate, and then acidifying the solution, adding more water causing FBI to precipitate out and recrystallizing from benzene.
- FBII another FluoraBora
- m-aminophenyl boronic acid is made by adding solid fluorescein isothiocyanate to an aqueous alkaline solution of m-aminophenyl boronic acid.
- ReportaBoras listed in Table I are not fluorescent, but rather contain reporter groups such as chromophores or derivatives of therapeutic agents.
- the reporter group can also be an antigen or an isotopically-labelled group, or it can be an organometallic group, as in compounds 8 and 15 of Table III.
- Compound 12 of Table III also contains an organometallic group, and in addition contains the fluorescent dansyl reporter group.
- Compound 8 is made according to the reaction diagrammed below.
- any desired organometallic complex can be used to make a ReporterBora, which in turn can be combined with a CarrierCeptor to make a BorAdept reagent.
- other useful organometallic complexes contain heavy, electron-opaque metals such as osmium, which are useful in staining for electron microscopy.
- ReportaBoras of Table I possess such poor water solubility that they cannot be presented to and taken up by living cells under non-toxic, physiological conditions. Such compounds, as has been discussed, are rendered useful for vital staining only when coupled to a CarrierCeptor.
- ReportaBoras e.g., FBI
- Such ReportaBoras are generally used for selective vital staining in the same manner as are BorAdept vital stains, described above.
- ReportaBoras and ReporterCeptors can also be used to selectively stain fixed cells, using conventional techniques and solvents. As with vital staining, the selectivity provided by the boronic acid portion of the ReportaBoras can provide valuable diagnostic information.
- ReportaBoras are useful for vitally staining the surfaces of cells and extracellular areas, and are also useful for staining the eye surfaces of living animals to determine the location of surface irregularities such as scratches and lesions; the negatively charged ReportaBoras are particularly useful for the latter purpose.
- the desired Reporta3ora dissolved in a physiological buffer or CarrierCeptor as a formula (1) complex, is applied in any conventional manner, e.g., with an eyedropper.
- FluroaBoras can be bound to certain water-insoluble supports and used in peroxide and other assay methods.
- the supports which can be used include all organic, water-insoluble polymeric materials having hydroxyl groups which can complex with boronic acids.
- suitable supports are polymers containing polyglycerol methacrylate, and hydrophilic fibrous polyethylene containing attached polyvinyl alcohol; the latter support is available from Crown Zellerbach under the name "Fybrel".
- Support-bound FluoraBoras preferably are made by reacting a solubilized FluoraBora (in acetone, benzene, DMF, or the like) with the powdered form of an appropriate support material and then washing the powder with a solvent to remove excess FluoraBora.
- a solubilized FluoraBora in acetone, benzene, DMF, or the like
- the FluroaBora being used is water-insoluble, it is first complexed with a suitable CarrierCeptor to form a formula (1) BorAdept compound, as described above.
- a CarrierCeptor it and the support should be chosen so that the support tends to form stronger complexes with the boronate of the FluoraBora being used, at the pH under which the reaction is carried out, then does the CarrierCeptor at that pH.
- the equation (3) equilibrium then allows the support to act as a separatory funnel, complexing with dissociated FluoraBora.
- a weakly complexing buffer such as MOPSO will be used in this situation.
- FluoraBoras bonded to Fybrel are particularly preferred embodiments of this aspect of the invention.
- the structure of FBI so bound is shown below. It can be seen that the boron atom forms a stable 6-membered ring with three carbons and two oxygens of the polyvinyl alcohol.
- FBI bound to Fybrel is made as follows. FBI is dissolved in acetone. Fybrel is ground to coarse powder and shaken with the dissolved FBI for 5 minutes. After exhaustive washing with acetone, support-bound FBI is stored in the dark at 5°C until used, either dry or in an organic solvent. Peroxide Assay
- Flow Chart I (Fig. 1) diagrams a method for assaying, in aqueous solution, a compound which participates in a chemical procedure which results in the production of peroxide.
- the basic principle is the same as that of the BorAdept peroxide assay, previously described.
- Excesses. of all of the reactants participating in the procedure are introduced into a reaction zone, e.g., a test tube, along with the sample containing an unknown amount of the compound to be assayed.
- the peroxide produced is brought into contact with a support-bound FluoraBora, described above.
- the peroxide breaks the carbon-boron bond of the boronic acid, releasing fluorescent compound into solution, where it can be measured directly using, e.g., a fluorometer, enhanced using a protein such as serum albumin, or extracted using a water-immiscible organic solvent such as ethyl acetate.
- the rate of release of fluorescent compound can be increased by maintaining the pH of the reaction zone in the range of about 8 to 9.
- the assay can be further modified by separating fluorescent compound in solution from the insoluble support folllowing the oxidation of the carbon-boron bonds by the peroxide. This separating can be carried out by filtering, by removing the insoluble support using centrifugation, or by extracting the dissolved fluorescent compound in an organic, water-immiscible solvent.
- Glucose is an example of a compound which can be assayed using the above-described method.
- a sample in aqueous solution, containing an unknown amount of glucose are added aqueous buffer of pH 8 to 9, glucose oxidase, and an excess of FBI bound to Fybrel.
- the Fybrel is filtered out and fluorophore is measured, using a fluorometer, as a measure of glucose in the sample.
- tube 2 contains an excess of a support-bound FluoraBora, described above.
- tube 1 Into tube 1 are introduced, in aqueous solution, excesses of all of the reactants, except the compound to be assayed, necessary to produce peroxide in the procedure being measured.
- tube 1 is pushed down to allow the fluorophore in solution to pass upward through filter 4.
- the fluorescence of the solution, or of an extract of the solution, a measure of the compound being assayed in the sample is measured with a fluorometer.
- the stable bond formed between FluoraBoras and supports containing hydroxyl groups and between FluoraBoras and certain other compounds, e.g., mucopolysaccharides, provides the basis for an assay for compounds having an affinity for boronic acids.
- the desired FluoraBora is contacted with an unknown amount of a compound to be assayed having an affinity for boronic acids.
- Another material having an affinity for boronic acids e.g., one of the supports discussed above, is then added to the mixture. This second material binds with FluoraBora which did not complex with the compound being assayed.
- the amount of FluoraBora bound to this second material is inversely proportional to the amount of unknown present.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Materials Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
Compounds having one of formulae I or II. In formula I, Rp1 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S, Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids. In formula II, Rp2 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S, Cg2 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
Description
REPORTER COMPOUNDS
Background of the Invention This application is a continuation-in-part of Gallop et al. "Fluorescent Boronic Acid-Contain ing Dyes", S.N. 132,908, filed March 24, 1980. This invention relates to reporter molecules such as dyes and drugs.
It is often desirable that such molecules be capable of being transferred from one phase to another; e.g., from an aqueous to a non-aqueous phase, or across biological membranes.
It is well-known that certain molecules can be rendered water soluble by the introduction into the molecule of a strongly basic or acidic group such as carboxylic acid or sulfonic acid, which confers water solubility by virtue of being ionized in aqueous solution at certain pH values. Summary of the Invention In one aspect, the invention features a new class of reagents which we have named the Boronate-Dependent Phase Transfer (BorAdept) compounds. The new compounds allow groups which can 1) report on conditions within living cells and tissues or 2) modify metabolic parameters within living tissues to be presented to and taken up by cells under non-toxic conditions.
or
In both formulae (1) and (2), each X and Y, independently, is N, O, or S, and r represents a receptor group which, with X and Y, forms adducts or complexes with boronic acids. Cg1 and Cg2 are carrier groups which each include a solubilizing group which is substantially ionizable in water, and Rp1 and Rp2 are groups which each include a reporter group which is a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group. The new compounds, because of their water-solubility at or near physiological pH, provide reporter groups with greatly enhanced versatility. Further, the ability of formula (1) and (2) compounds to exist in pH-dependent equilibria with their dissociated forms renders them useful for a broad range of applications. Many of these compounds have the additional advantage provided by the boronic acid-derived portion of the molecule which, when dissociated from the remainder of the molecule, can exhibit the
selective affinity which boronic acids have for organic compounds having reactive hydroxyl, amino, and thiol groups, the aforesaid equilibria also allow some reporter groups to enter environments where their properties are advantageously altered. For example, some of the fluorescent reporter groups, under certain conditions, can be brought into contact with hydrophobic pockets in cells or organic phases where they exhibit enhanced or quenched fluorescence.
Other aspects of the invention feature applications of the new compounds such as the staining of living cells, proteins, and fabrics, and various assay methods. Among other aspects, the invention also features new boronic acid containing compounds, which are useful both by themselves, and as starting materials for BorAdept compounds.
Other advantages and features of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
Description of the Preferred Embodiments We turn now to a description of the preferred embodiments of the invention, after first briefly describing the drawings. Drawings
Figure 1 is a flow chart diagramming an assay method of the invention. Figure 2 is a perspective view of apparatus for carrying out one of said methods.
BorAdept Compounds
The compounds represented in formula (1) and (2) each is a reaction product between a compound which includes a boronic acid, and a compound which includes a receptor group (r) which, with X and Y, forms adducts or complexes with boronic acids. In both cases, one of the compounds also includes a group (Rp1 or Rp2) which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group. The other compound includes a carrier group (Cg1 or Cg2) which includes a strongly basic or acidic solubilizing group which is substantially ionizable in water. Rp1 is bonded to boronic acid in formula (1), while Rp2 is bonded to the receptor in formula (2). Cg1 is bonded to the receptor in formula (1), while Cg2 is bonded to boronic acid in formula (2).
The compounds of formula (1) are generally made by the reaction
An important feature of reactions (3) and (4) is that, in aqueous solution, both are reversible; i.e., the BorAdept reagents are in dynamic equilibria with their starting materials. The extent to which, under a given set of circumstances, an equilibrium is pushed in either direction in part determines a compound's usefulness for a given application. The extent to which the equilibrium is pushed toward the formation of the water-soluble formula (1) or (2) compound, at the expense of the starting materials (i.e., push to the right) is dependent on several factors, including the pKa and Lewis acid complexing strength of the boronic acid, the
complexing potential of and the local net
charge and hydrophobicity of Rp1 or RP2. The compounds of formula (1) and (2) can, if desired, contain more than one reporter group, and in such case the properties of the additional
group or groups can influence the dynamic equilibrium of the compound.
Turning now to a more detailed description of the compounds of formula (1), the CarrierCeptor
portion of the molecule, most
frequently is of one of three general configurations, so that the formula (1) compound has one of the following general formulae:
In formulae (5), (6), and (7), each R2 - R7, independently, is hydrogen, aryl, alkyl, heteroalkyl, hetroaryl, aralkyl, or a solubilizing group which is substantially ionized in water, provided that the compound contains at least one such solubilizing group. Each of n and m, independently, is 0, 2, or 3, provided that both cannot be 0. When n or m is 2 or 3, each R2 - R5 can be different in successive repeating units. For example, where n is 2, the R2 attached to the first carbon atom can be hydrogen, while the R2 attached to the second carbon atom is a solubilizing group.
In the structure of formula (7), known as a transannular complex, the arrow from N to B indicates the attraction between the electron-deficient boron atom and the electron-rich nitrogen atom.
In formulae (5), (6), and (7), each of groups R2 - R7 preferably contains between 0 and about 12 carbon atoms. The solubilizing group is preferably a sulfonic acid, a carboxylic acid, quaternary ammonium, a guanidinium group, or a phosphate group. The first step in making a formula (1) compound is to make the desired ReportaBora. This can be done by reacting a desired organic boronic acid with the desired Rp1. Alternatively, the desired Rp1 precursor can undergo hydroboration with catechol boirane, or can participate in a
Grignard reaction with a boronate ester to make a ReportaBora. If desired, the reporter group can first be incorporated into a compound having a
desired property, e.g., good electron withdrawing power for enhanced activation of the boronate. Table I shows the structures of some ReportaBora compounds which provide the Rp1-B portion of the compounds of formula (1) . Each of these can react with any CarrierCeptor, as defined above, to produce a formula (1) compound. Table I also indicates the utility of the reporter group of each listed ReportaBora. This utility, along with other factors, including choice of CarrierCeptor, allows the choice of starting materials which will react to produce a formula (1) compound possessing the properties required for a given application. Table II shows the structures and some properties of some preferred CarrierCeptor
compounds which provide
formula (1) compounds. These CarrierCeptors can be reacted with any ReportaBora, such as those listed in Table I, to make a compound of the general formula (1).
Some of the CarrierCeptors listed in Table II are biologically compatible buffers which have been described in publications from the laboratory of Good, as summarized in Ferguson et al. (1980) Analyt. Biochem. 104, 300; this paper itself also describes suitable buffers. Only the buffers described in the aforementioned literature which
contain the group, as defined herein,
are suitable for making the compounds of formula (l). Table III shows the structures of some
preferred formula (1) compounds made with suitable buffers.
Turning now to a more detailed description
of the compounds of formula (2), the portion
of the molecule, as in the case of formula (1) compounds, typically has one of three general configurations, Cg2 typically includes both a solubilizing group and an organic group linking the solubilizing group to the boron atom. Formula (2) compounds thus typically have one of the following general formulae:
In formulae (8), (9), and (10), Sol is the aforementioned strongly basic or acidic solubilizing group and A1 is alkyl, aryl, heteroaryl, heteroalkyl, or aralkyl; most preferably A1 contains between 3 and about 12 carbon atoms. Each A2 - A7, independently, is hydrogen, aryl, alkyl, hetoralkyl, heteroaryl, aralkyl, or Rp2, the group containing a reporter group, provided that the compound contains at least one Rp2. Each of A2 - A7, except Rp2, preferably contains between 0 and about 12 carbon atoms.
Each of p and q, independently, is 0, 2, or 3, provided that both cannot be 0. When p or q is 2 or 3, each A2 - A4 can be different in successive repeating units. For example, where p is 2, the A2 attached to the first carbon atom can be hydrogen, while the A2 attached to the second carbon atom can be Rp2.
The first step in making a formula (2) compound is to make the desired ReporterCeptor by
Rp2 can consist entirely of the desired reporter group, or the reporter group can be incorporated
into an Rp2 having a desired property; e.g., good
reactivity with The can be any
compound which forms adducts or complexes with boronic acids. For example, any of the
CarrierCeptors of Table II, with or without their
A large number of CarrierBoras can be made and reacted with a ReporterCeptor to produce a formula (2). However, there is little advantage
(putting aside considerations such as cost) in having a wide variety of CarrierBoras to choose from, and one or a few can be reacted with a wide variety of ReporterCeptors. An example of one such versatile CarrierBora is the compound shown below which, although not commercially available, can be made using conventional methods.
Compound (11) is particularly useful because its boronate group is highly reactive as a result of the strong electron withdrawing action of the sulfonephenyl group
Other examples of CarrierBoras are m-carboxyphenyl boronic acid, p-sulfophenylboronic acid, m-guanidinophenyl boronic acid, and p-trimethylammoniumphenyl boronic acid. The first two are negatively charged, while the latter two are positively charged.
If it is desired to bond a reporter group not only to the boronic acid part of the CarrierBora, but to the linking group as well, it is necessary to provide a reactive site on the A1 portion of the CarrierBora. An example of a CarrierBora having such a site (NH) is
Compound 12 is made by reacting m-aminophenyl boronic acid, in aqueous ethanol at pH 8.0, with
A formula (2) compound is typically made by dissolving the desired ReporterCeptor in anorganic, water-miscible solvent, e.g., dimethyl acetamide, acetone, or dimethyl formamide, and then adding an excess of the desired CarrierBora in
water or an appropriate aqueous buffer. Some preferred formula (2) compounds are listed in Table IV.
Both formula (1) and formula (2) compounds can, if desired, contain more than one reporter group. A group, Rp3 including a second reporter group can be attached at any suitable reactive site on formula (1) or (2) compounds, but will most often be attached at a site on Rp1 or Rp2 so that the ReportaBora or ReporterCeptor, dissociated from the carrier part of the molecule, bears both reporter groups. Compound 3 of Table III, an example of such a compound, bears two staining reporter groups. Depending on the application, it can also be advantageous to include, in one compound, any of a number of combinations of two or more reporter groups, e.g., a therapeutic agent together with an isotopically-labelled group, or a fluorophore together with an antigen. Staining of Living Cells,
Proteins, and Other Materials
The compounds of both formulae (1) and (2) in which the reporter group is a chromophore, an antigen, an organometallic group, an isotopically-labelled group, or a fluorophore are useful for staining living cells, proteins, and other materials such as fabrics and paper products.
The cell-staining formula (1) compounds
(hereinafter referred to as "stains") behave differently from those of formula (2), and will be discussed separately.
As shown in equation (3), formula (1) compounds, in aqueous solution at pH values around
physiological pH, exist in dynamic equilibria with their starting materials. The equilibrium permits the presentation of the ReportaBora to cells in media compatible with living cells, and uptake by cell membranes without toxicity.
The diagram below illustrates the mechanism of uptake of ReportaBora by cells. The scheme is general, and is not strictly applicable to all formula (1) compounds. For example, a formula (1) compound having a positively-charged solubilizing group such as quaternary ammonium is more likely to enter the cell intact rather than operating as shown below. Also, many ReportaBoras do not exhibit altered reporting properties inside cells.
As shown in the diagram, the equation (3) equilibrium permits hydrophobic pockets of the cell membrane to selectively extract ReportaBora, which then enters the cell. Once inside the cell, the ReportaBora, carried by lipophillic components of the cell, is capable of selectively staining cellular components. The boronic acid portion of the molecule binds selectively to certain biological groups within cells which contain appropriately distributed hydroxyl, amino, and thiol groups; binding is particularly favored when such groups are in non-aqueous regions of the cell. Certain complex lipids, mucopolysaccharides, liposaccharides, glycoproteins, and proteins contain such reactive groups. Other compounds, e.g., certain conjugated proteins, also contain such reactive groups in appropriate complexing positions resulting from their sequences, confirmations, and configurations. The selectivity of formula (1) compounds makes them useful as vital cellular stains in the diagnosis of certain disease states, including certain genetic disorders, particularly those which cause mucopolysaccharidosis, liposaccharidosis, or an increase in either the number or size of cellular lysosomal components. For example, Hurler's Syndrome, Hunter's Syndrome, and β-glucuronidase deficiency can be diagnosed by culturing a patient's cells, staining them with a fluorescent formula (1) stain, e.g., compound 1 of Table III, and then examining them using a fluorescent microscope. The vital staining
patterns and the rate of destaining of certain cellular particulates can provide valuable diagnostic information. The compounds are also useful for gaging the viability and motility of human and animal sperm.
The selectivity of formula (1) compounds also makes them useful in comparing staining patterns of various cells in different cell cycle stages. The stains can also be useful for staining catecholamine-rich regions of cells; for example, the compounds stain epinephrine, norepinephrine, dopamine, di-hydroxyphenylalanine, and 3, 4-hydroxphenylacetic acid, compounds which are abundant in nervous and adrenal tissue and are thus useful for the diagnosis of a variety of clinical conditions.
Staining of cells can be carried out using any most conventional vital staining techniques, but is preferably carried out according to either of the following two preferred processes.
According to one preferred process, cells to be stained, e.g., fibroblasts, are grown on a coverslip, the culture medium is poured off, the cells are washed with physiological buffer several times, and the coverslip is covered for 5 minutes with a formula (1) compound dissolved in physiological buffer. The coverslip is then washed, turned over onto a slide, and examined using a light or fluorescent microscope, or processed further, e.g., tested for the presence of immune complexes, radioactive label, or heavy metals.
According to another preferred staining method, ReportaBora is added directly to the cell culture medium in which CarrierCeptor is already present as the buffer. After the desired degree of staining is complete, the medium is poured off and the cells are examined.
An additional step may be added to either preferred staining method to obtain additional information, such as the relative dynamic stability of the bonds between the stain and various cellular components. After staining, cells are transferred to fresh culture medium and monitored to determine the relative rates at which the stain leaches out of various cellular components. When the formula (1) compound contains an organometallic electron opaque reporter group, following vital staining, the cells are fixed and prepared for examination with an electron microscope.
Although any formula (1) compounds can be used for vital staining, some are more useful than others for certain applications. One factor affecting choice of dye is the strength of the bond between the ReportaBora and the CarrierCeptor; very tight complexes, such as those formed with strong CarrierCeptors such as TAPSO, and with certain
ReportaBoras containing strong Lewis acid boronic acids, tend to make it more difficult for cell membranes to extract appreciable amounts of the ReportaBora. For this reason, it is sometimes preferable, for vital staining, to use a formula (1) stain made with a weaker complexing CarrierCeptor such as TES or MOPSO (Table II).
Because Carrier Ceptors which form weak complexes with boronic acids also tend to be less reactive with boronic acids, when it is desired to make a formula (1) compound using a weak CarrierCeptor such as MOPSO, it is often desirable to employ a more reactive ReportaBora; i.e., one in which the boron atom is more electron deficient. Such a reactive ReportaBora is one in which Rp contains a linking group, proximate to the boron atom, which has strong electron withdrawing power. Referring to Table I, FBIII contains the linking group
which, because of its relatively strong electron withdrawing action, renders FBIII able to complex to a considerable degree with weakly complexing CarrierCeptors such as MOPSO. In contrast ReportaBoras, e.g., FluoraBora I, containing groups such as the sulfamido linkage, which do not exert strong electron withdrawing action, complex to a lesser extent with weakly complexing CarrierCeptors, and formula (1) compounds wherein the ReportaBora is FluoraBora I are thus preferably made with a strong CarrierCeptor such as TAPSO.
Another factor which can influence the choice of formula (1) fluorescent stain for a particular application is whether the fluorophore is enhanced or quenched (inhibited) in hydrophobic
environments such as the hydrophobic protein pockets which the ReportaBora is likely to seek within a cell. Still another consideration is whether the fluorophore exhibits a shift in emission wavelength in such an environment; both enhancement and emission shift can advantageously increase detectability of dyes within cells.
As mentioned above, in the case of formula (1) stains in which the solubilizing group is a positively charged group such as the quanidiuium group (e.g., compound 7 of Table III), rather than just the ReportaBora entering the cell, the entire formula (1) compound may enter. After such a stain has entered a cell, hydrophobic regions of the cell compete with the CarrierCeptor portion for the ReportaBora portion, establishing local intracellular equation (3)-type equilibria. In the case of such a stain in which the reporter group is a fluorophore which is enhanced in hydrophobic environments, varying degrees of enhancement in different parts of a cell are correlated with varying degrees of hydrophobicity in those regions; this data can provide additional information about the properties of the cell. Formula (2) dyes can also be used for the vital staining of cells. The diagram below illustrates the mechanism of uptake of ReporterCeptor by cells. As with formula (1) compounds, there are exceptions to this general scheme.
Formula (2) dyes can also be used for the vital staining of cells. The diagram below illustrates the mechanism of uptake of ReporterCeptor by cells. As with formula (1) compounds, there are exceptions to this general scheme.
Cells are contacted with an aqueous solution of the stain, which is in dynamic equilibrium with its respective CarrierBora and ReporterCeptor. The cell selectively extracts ReporterCeptor molecules, which enter and stain the cells, and can exhibit altered reporting properties such as fluorescence enhancement or wavelength shift in hydrophobic regions of the cell. Unlike the reporter component of formula (1) stains, those of formula (2) stains are not boronic acids, and do not form such complexes with particular cellular components; their specificity depends instead on the nature of the receptor portion of the molecule. Formula (2) stains in which the solubilizing group is a positively charged group; e.g., quaternary ammonium, can also be used for
vital cell staining. As with formula (1) stains containing such groups, the entire compound may enter the cell and establish local hydrophobicity- dependent equilibria within the cell.
A further refinement to vital cell staining using formula (1) and (2) compounds is to employ a stain having more than one staining reporter group. For example, a formula (1) stain
can have the structure
where Rp1 and Rp3 each is a group which includes a fluorophore, chromophore, an antigen, an isotopically-labelled group, or an organometallic compound. Compound 12 of Table I, complexed with TAPSO (Table II) is an example of such a compound, bearing a fluorophore which provides cellular information at the level of the fluorescent microscope, and an electron-opaque organometallic group which provides information on the electron microscope level; the fluorescence pattern of a stained cell indicates to the electron microscopist that that cell took up stain, indicates which portions of the cell were stained at the level of resolution of the light microscope, and, after preparation for electron microscopy, allows a comparison of staining patterns within the same cell at the light and ultrastructural levels.
The formula (1) stains can also be used to permanently stain proteins. The preferred method for carrying out such staining is to react the protein to be stained with the dye under mild conditions; e.g., at room temperature or lower, at
pH 4 to 10, in the absence of an organic solvent. Excess ReportaBora can then be removed by carrying out dialysis against the CarrierCeptor used to make the stain. For example, to stain serum albumin, compound 9 (Table III) is first made by dissolving highly water-insoluble ChromaBora II (CBII) (Table I) in a very small volume of dimethyl acetamide and then in an excess of TAPSO at pH 9.0. Serum albumin is then added and the mixture then dialyzed against TAPSO to remove excess CBII. Before the dialysis, CBII enters the hydrophobic pockets of serum albumin, leaving its CarrierCeptor, TAPSO, in the aqueous phase. Dialysis against TAPSO removes excess CBII as the formula (1) complex, but is unable to remove CBII from the hydrophobic pockets of the serum albumin, which is thus permanently stained.
Formula (1) and (2) compounds can also be used to stain or brighten a variety of other materials such as fabrics and paper products.
Staining is carried out by simply contacting the material to be stained with an aqueous solution of the desired formula (1) or (2) compound (generally a colored or a fluorescent compound) until the desired degree of staining has been achieved. Brightening of fabrics is carried out using a fluorescent formula (1) or (2) compound, and can often be performed in a conventional clothes washing machine, in soapy or clean water. Many fabrics can be brightened using the new compounds, including cellulose-containing fabrics, such as cotton and linen, and nitrogen-containing
fabrics such as wool and silk, and various synthetics. When brightening a cellulose-containing fabric, it is preferable to use formula (1) compounds, because the FluoraBora of the equation (3) equilibrium is attracted to the hydroxyl groups of the fabric.
When brightening a nitrogen-containing compound such as wool, formula (1) dyes are also preferred, and the brightening process may include an additional step. Following the step of contacting the fabric with the fluorescent formula (1) compound, the fabric is contacted with an oxidizing agent such as peroxide, which breaks the carbon-boron bond of the formula (1) compound, releasing Rp1 - OH, which is then. better locked into the hydrophobic pockets in the fabric. Even greater brightening can be obtained by employing a formula (1) compound in which the fluorescent part of the molecule exhibits enhanced fluorescence in hydrophobic environments. Peroxide and Enzyme Assays
A colored or fluorescent formula (1) compound can be used to measure, in aqueous solution, an unknown amount of a compound which participates in an enzymatic procedure ("procedure", as used herein, includes one or a series of reactions) in which an enzyme acts on a substrate, or a chemical procedure which results in the production of peroxide. In the peroxide assay, excesses of all of the reactants participating in the procedure are introduced into a reaction zone, e.g., a test tube,
along with the sample containing an unknown amount of the compound to be assayed. The peroxide produced is brought into contact with a known amount of the formula (1) compound. The peroxide, an oxidizing agent, breaks the carbon-boron bond of the ChromoBora or FluoroBora, releasing Rp1 - OH, which is then contacted with a substance having a greater affinity for Rp1 - OH than for the formula (1) compound. The fluorescence or color intensity of the substance is then measured as a measure of the unknown amount of the compound being assayed.
The selective affinity substance can be a water-immiscible organic solvent which is capable of extracting Rp1 - OH away from the formula (1) compound. The solvent forms a fluorescent organic layer separate from the aqueous layer; if desired the two layers can then be separated to facilitate quantification of the fluorescence of the organic layer.
One factor which influences the choice of formula (1) compound when a water-immiscible organic solvent is to be used is the tightness of the complex between the ReportaBora and the CarrierCeptor. Compounds in which the complex is very tight are most preferred because a looser complex may be broken between the boronate and the CarrierCeptor, thus allowing the colored or fluorescent starting material, along the Rp1 - OH, to be partially extracted by the solvent.
Furthermore, in the case of a looser complex, the tendency of the organic solvent to push the
equation (3) equilibrium toward dissociation of the complex by extraction of the ReportaBora may overshadow a comparatively smaller peroxide effect. Table V shows the extent to which three FluoraBoras, complexed with six CarrierCeptors in aqueous solution, are extracted into ethyl acetate. Of the compounds of Table V, those made with comparatively tightly-complexing TAPSO are most preferred for the peroxide assay because, absent peroxide (i.e., in a blank reaction), a comparatively large proportion of the fluorescence remains in aqueous solution, unextracted by ethyl acetate. Compounds in which the complex is even tighter, so that the blank extraction value is still lower, would be even more desirable.
Another factor influencing the aforesaid choice, when the reporter group of the formula (1) compound is a fluorophore, is the manner in which the organic solvent being used affects the properties of the fluorophore. Some fluorophores are enhanced, i.e., their fluorescence is made more intense, in a given organic solvent, while others exhibit diminished fluorescence (quenching). Some fluorophores may also exhibit altered emission spectra in certain organic solvents. Although any fluorescent formula (1) compound can be used, provided its fluorophore is not totally quenched in the organic solvent, both enhancement and spectrum alteration desirably heighten detectability. Table VI shows the relative fluorescence of three FluoraBoras combined with TAPSO, compared to the fluorescence of equal concentrations of
FluoraBora in the water-immiscible organic solvent ethyl acetate. Because FBPA and FBI are enhanced (two and seven-fold, respectively), formula (1) compounds made with them are suitable for use in the peroxide assay described above. FBIII, on the other hand, is quenched to a large extent in ethyl acetate, and formula (1) compounds made with it are therefore not desirable for use in the assay in which ethyl acetate is employed. Instead of a water-immiscible organic solvent, the selective affinity substance in the peroxide assay can be a water-miscible protein which has a greater affinity for Rp1 than for the corresponding formula (1) compound being used. Preferred proteins are those, e.g., serum albumin, which posses hydrophobic pockets which can attract Rp1.
When such a protein is used, it is necessary that the formula (1) compound be fluorescent, and that the protein be capable of producing an observable effect, preferably enhancement or, less preferably, quenching, of fluorescence, of Rp1, there being no easily observed water/protein phase separation. Table VII shows the relative enhancement or inhibition with serum albumin, of the three fluorophores of eighteen formula (1) compounds. Table VII shows that, in general, FBI and, to a lesser extent, FBPA, are enhanced in serum albumin, while FBIII exhibits diminished fluorescence.
The extent to which each of the three fluorophores of Table VII is enhanced or inhibited
depends, to a significant extent, on the CarrierCeptor with which it is combined. Thus, enhancement, in serum albumin, of FBPA and FBI, and inhibition of FBIII, is much greater if the formula (1) compound has been made with loosely complexing MOPSO than with tightly complexing TAPSO. This is because the loose Rp1-MOPSO complex favors an equilibrium in which more free Rp1 is available to seek the hydrophobic pockets of serum albumin, where enhancement or inhibition of fluorescence occurs. Before performing an assay, therefore, a blank should always be run in which the peroxide-generating reagents are not added, so that enhancement or inhibition in the absence and presence of those reagents can be compared. The other observable effect which a water-miscible protein such as serum albumin can have on a fluorophore is a shift in the peak emission spectrum; such a shift can, as in the case of a water-immiscible organic solvent, aid detectability. FBPA, for example, normally emits at 460 nm, while its dissociated fluorophore, in the hydrophobic pockets of serum albumin, emits at 427 nm. Glucose is an example of a compound which can be measured using the above-described method. A sample containing an unknown amount of glucose is placed in a test tube with a known amount of Compound 1 (Table III) and a known amount of serum albumin in aqueous solution at pH between 8 and 9. An excess of glucose oxidase is then added, and the increse in fluorescence compared to that of a
no-enzyme, no-substrate blank is measured as a measure of the amount of peroxide produced, which in turn is a measure of the amount of glucose in the sample. Here, glucose oxidase catalyzes the oxidation of glucose to gluconic acid by oxygen, forming H2O2. The H2O2 oxidizes the C-B bond of FBI in the formula (1) complex, forming dansylamido phenol, which enters the serum albumin pockets, where it exhibits enhanced fluorescence. Using principles similar to those just described, certain formula (1) compounds can also be used to measure an unknown amount of a compound which participates in an enzymatic procedure in which an enzyme acts on a substrate. The method employs fluorescent formula (1) compounds in which Rp, includes a group, positioned between the boron atom and the fluorophore, capable of acting as a substrate for the enzyme. A desired enzyme substrate can be incorporated into a desired formula (1) compound using coventional techniques.
According to the assay methods, the formula (1) compound being used is introduced into a reaction zone, along with excesses of all of the other participating reactants except the compound to be measured, and a sample containing the compound to be measured. The enzymatic reaction releases modified fluorophore which, after completion of the reaction, is contacted with a water-immiscible organic solvent or a water-miscible protein, as described above for the peroxide assay. The extent of fluorophore
extraction or fluorescence enhancement or inhibition is then measured versus a blank, as described above, as a measure of the unknown compound. If a water-miscible protein is used, the rate of the enzymatic reaction can also be followed by measuring the rate at which fluorescence enhancement increases.
Esterases such as Upases are examples of compounds which can be assayed using this method. In a test tube, in aqueous solution, is placed a known amount of compound 6 (Table III), of the formula
A sample containing an unknown amount of lipase is then added. Lipase present in the sample breaks the ester bond (as indicated by the dotted line), releasing modified Rp1, containing the fluorescent dansyl group, which is then extracted or contacted with a known amount of serum albumin and fluorescence measured, as described above for the peroxide assay. Antibody Assay Another new assay employing formula (1) compounds is an antibody assay employing red blood
cells. (Red Blood cells are commonly used in other antibody assays.) A formula (1) compound is used in which the reporter group of Rp1 is a hapten capable of complexing with the antibody being assayed. Red blood cells are contacted, in aqueous solution, with the formula (1) compound, which is in an equation (3)-type equilibrium with its starting materials. The red blood cell membrane selectively extracts hapten-containing ReportaBora, thus becoming sensitized. The sensitized red blood cells are contacted with a sample containing an unknown amount of antibody, together with complement which is capable of participating in the complexation of the hapten with the antibody. The antibody in the sample complexes with the hapten in the sensitized cell membrane, fixing complement and causing cell lysis and the release of hemoglobin from the cell. The amount of hemoglobin released is a measure of the amount of antibody in the sample.
A modification of the above-described procedure can be performed using red blood cell ghosts or membranes rather than intact cells. According to this modification, the formula (1) compound used contains two reporter groups; a hapten and a fluorophore, both of which become incorporated into the membranes of sensitized red cell ghosts by the BorAdept process. When the ghosts are contacted with antibody and complement, lysis of the ghost stroma occurs, causing the release of soluble fragments containing fluorophore. If desired, the solution can contain
a CarrierCeptor to facilitate solubilization of the fluorescent fragments. The fluorescence in solution is then measured as a measure of the antibody titer. Solubilization of Therapeutic Agents
The BorAdept system of the invention can greatly facilitate the administration of therapeutic agents such as drugs which have heretofor been difficult to administer because of poor water solubility or difficult to test in cell culture systems. A desired therapeutic agent can be incorporated into either a formula (1) or (2) compound. In either case, by virtue of the equation (3) or (4) equilibrium, the agent is not only solubilized, but is in a form which enables the agent to be presented to and taken up by cells to which it is desired to deliver the agent, by the same mechanism by which fluorophore reporter groups are taken up by cells to be stained. Therapeutic formula (1) compounds are generally made in the same way fluorescent formula (1) compounds are made; i.e., the de-sired therapeutic agent or a suitable precursor or derivative thereof is first reacted with the desired boronic acid to form a ReportaBora (in this case, a TheraBora), which is then reacted with the desired CarrierCeptor. The boronic acid is preferably chosen to include a group which renders the boronic acid reactive with the therapeutic agent being used.
Compound 4 of Table III is an example of a formula (1) compound containing a derivative of
therapeutic agent, the water-insoluble anti convulsant diphenyl hydantoin. Another example is compound 2 of Table III, containing a derivative of the water-soluble anti-epileptic drug carbamazepine. This new compound is made according to the reaction scheme illustrated on the following page.
Therapeutic formula (2) compounds are generally made in the same way that fluorescent formula (2) compounds are made, i.e., the desired therapeutic agent or a suitable precursor or derivative thereof is, if necessary, incorporated into a compound having a desired property to make Rp2, which is then reacted with a compound of the
Compound 5 of Table IV is made according to the reaction scheme illustrated on the following pages:
Table I lists some preferred ReportaBoras of the invention. These new compounds, as is discussed above, are useful in making formula (1) BorAdept compounds. In addition, we have discovered that they have many applications by themselves, even when not complexed with a CarrierCeptor in a formula (1) compound. Many of these applications, e.g., the peroxide assay, are similar in principle to applications of formula (1) compounds.
The ReportaBoras of the invention are generally made by reacting a desired reporter group-containing compound (Rp4) with a desired organic boronic acid capable of reacting with that
Rp4.
Usually the organic boronic acid has the general formula
where Ro is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl, and Z is a group capable of chemically combining with the Rp4 being used. Preferably,
Ro contains between 3 and about 25 carbon atoms.
A preferred (because of ready availability) boronic acid is m-aminophenyl boronic acid, in which Z is
NH and Ro is
Rp4 usually has the formula
where Re is the reporter group and Y is a group capable of chemically combining with the Z portion of the boronic acid being used.
The ReportaBoras made by reacting the aforesaid boronic acids and Rp4's thus either have the formula
depending on whether Y is entirely lost in the course of the reaction.
In some preferred boronic acids, Z is NH2, OH, SH, or COOH, and in some preferred
X being any halogen. In ReporterBoras made from these starting materials, the carbon or sulfur atom of Y to which X was bonded bonds to Z, replacing an H. Z' is thus Z minus an H, and Y' is Y minus X. (there is no Y' when Y consists entirely of X).
The boronic acids wherein Z is NH2 can also react with Rp4's in which Y is N=C=V, where V is O or S. The resulting ReportaBoras have the formula.
One of the most preferred new ReportaBoras we have synthesized is referred to in Table I as "FBPA". This compound is made using a diaryl pyrazoline sulfonic acid, supplied to us as a gift by Ilford Limited, Basildon - Essex, England. Ilford's fluorescent compound has the formula
The first step in our synthesis of FBPA is to make the sulfonyl chloride of Ilford's compound by reacting it with PCl5. The new sulfonyl chloride has the formula:
The new compound has a chemically stable crystalline structure with a melting point of 119°C. Besides being useful for making ReportaBoras, it is, also useful as a fluorescent reporter for labelling proteins such as antibodies and other compounds such as amino acids and polyamines. Because of its azuxe fluorescence, it can be used in conjunction with red and yellow fluorescent dyes in immunofluorescent labelling experiments.
Compound 21 is a diaryl sulfonyl chloride, and is one of a family of fluorescent compounds which we refer to as DARPSYL chlorides. These compounds are the sulfonyl chloride derivatives of compounds of the general formula
where one of Ar1 or Ar2 is an aromatic group containing a sulfonyl chloride group and Q is hydrogen or an alkyl group. The compounds in which Ar1 contains the sulfonyl chloride group are the "A" compounds, and are derived from the DARPSYL compounds described in British Pat. No. 670,857. The sulfonyl chloride derivatives in which Ar2 contains a sulfonyl chloride group are the "B" compounds, and are also useful fluorescent stains. The new A-DARPSYL chloride, (compound 21), as well as other DARPSYL-chlorides, can be combined with organic boronic acids to make useful FluoraBoras. To make FBPA (Table I), the A-DARPSYL chloride described above is combined with m-aminophenyl boronic acid in DMF-H2O. The mixture is then acidified, water is added causing FBPA to precipitate out and recrystallization is carried out, from cyclohexane.
Another FluoraBora listed in Table I, FBI, is made by adding an acetone solution of dansyl chloride to an aqueous acetone solution of m-aminophenyl boronic acid hemisulfate containing 2.5 equivalents of sodium bicarbonate, and then acidifying the solution, adding more water causing FBI to precipitate out and recrystallizing from benzene.
FBII, another FluoraBora, is made by adding solid fluorescein isothiocyanate to an aqueous alkaline solution of m-aminophenyl boronic acid.
Many of the ReportaBoras listed in Table I are not fluorescent, but rather contain reporter groups such as chromophores or derivatives of therapeutic agents. The reporter group can also be an antigen or an isotopically-labelled group, or it can be an organometallic group, as in compounds 8 and 15 of Table III. Compound 12 of Table III also contains an organometallic group, and in addition contains the fluorescent dansyl reporter group. Compound 8 is made according to the reaction diagrammed below.
In addition to the mercury and iron-containing complexes of the compounds of Table I, any desired organometallic complex can be used to make a ReporterBora, which in turn can be combined with a CarrierCeptor to make a BorAdept reagent. As is mentioned above, other useful organometallic complexes contain heavy, electron-opaque metals such as osmium, which are useful in staining for electron microscopy. Cell Staining with ReportaBoras
Many of the ReportaBoras of Table I possess such poor water solubility that they cannot be presented to and taken up by living cells under non-toxic, physiological conditions. Such compounds, as has been discussed, are rendered useful for vital staining only when coupled to a CarrierCeptor.
Some ReportaBoras, e.g., FBI, however, are sufficiently water-soluble, and possess the necessary neutral or positive charge and are sufficiently hydrophobic, to be useful directly as vital stains. Such ReportaBoras are generally used for selective vital staining in the same manner as are BorAdept vital stains, described above. ReportaBoras and ReporterCeptors can also be used to selectively stain fixed cells, using conventional techniques and solvents. As with vital staining, the selectivity provided by the boronic acid portion of the ReportaBoras can provide valuable diagnostic information.
Certain non-toxic ReportaBoras are useful for vitally staining the surfaces of cells and extracellular areas, and are also useful for staining the eye surfaces of living animals to determine the location of surface irregularities such as scratches and lesions; the negatively charged ReportaBoras are particularly useful for the latter purpose. To stain eye surfaces, the desired Reporta3ora, dissolved in a physiological buffer or CarrierCeptor as a formula (1) complex, is applied in any conventional manner, e.g., with an eyedropper. Support-bound FluoraBoras
FluroaBoras can be bound to certain water-insoluble supports and used in peroxide and other assay methods. The supports which can be used include all organic, water-insoluble polymeric materials having hydroxyl groups which can complex with boronic acids. Examples of suitable supports are polymers containing polyglycerol methacrylate, and hydrophilic fibrous polyethylene containing attached polyvinyl alcohol; the latter support is available from Crown Zellerbach under the name "Fybrel". Support-bound FluoraBoras preferably are made by reacting a solubilized FluoraBora (in acetone, benzene, DMF, or the like) with the powdered form of an appropriate support material and then washing the powder with a solvent to remove excess FluoraBora. Alternatively, if the FluroaBora being used is water-insoluble, it is
first complexed with a suitable CarrierCeptor to form a formula (1) BorAdept compound, as described above. If a CarrierCeptor is used, it and the support should be chosen so that the support tends to form stronger complexes with the boronate of the FluoraBora being used, at the pH under which the reaction is carried out, then does the CarrierCeptor at that pH. The equation (3) equilibrium then allows the support to act as a separatory funnel, complexing with dissociated FluoraBora. Usually a weakly complexing buffer such as MOPSO will be used in this situation.
FluoraBoras bonded to Fybrel are particularly preferred embodiments of this aspect of the invention. The structure of FBI so bound is shown below. It can be seen that the boron atom forms a stable 6-membered ring with three carbons and two oxygens of the polyvinyl alcohol.
FBI bound to Fybrel is made as follows. FBI is dissolved in acetone. Fybrel is ground to coarse powder and shaken with the dissolved FBI for 5 minutes. After exhaustive washing with acetone, support-bound FBI is stored in the dark at 5°C until used, either dry or in an organic solvent. Peroxide Assay
Flow Chart I (Fig. 1) diagrams a method for assaying, in aqueous solution, a compound which participates in a chemical procedure which results in the production of peroxide. The basic principle is the same as that of the BorAdept peroxide assay, previously described. Excesses. of all of the reactants participating in the procedure are introduced into a reaction zone, e.g., a test tube, along with the sample containing an unknown amount of the compound to be assayed. The peroxide produced is brought into contact with a support-bound FluoraBora, described above. The peroxide, an oxidizing agent, breaks the carbon-boron bond of the boronic acid, releasing fluorescent compound into solution, where it can be measured directly using, e.g., a fluorometer, enhanced using a protein such as serum albumin, or extracted using a water-immiscible organic solvent such as ethyl acetate.
The rate of release of fluorescent compound can be increased by maintaining the pH of the reaction zone in the range of about 8 to 9. The assay can be further modified by separating fluorescent compound in solution from the insoluble support folllowing the oxidation of the carbon-boron bonds by the peroxide. This
separating can be carried out by filtering, by removing the insoluble support using centrifugation, or by extracting the dissolved fluorescent compound in an organic, water-immiscible solvent.
Glucose is an example of a compound which can be assayed using the above-described method. To a sample, in aqueous solution, containing an unknown amount of glucose are added aqueous buffer of pH 8 to 9, glucose oxidase, and an excess of FBI bound to Fybrel. After the release of fluorescent compound into solution has been completed, the Fybrel is filtered out and fluorophore is measured, using a fluorometer, as a measure of glucose in the sample.
Apparatus useful in the practice of the peroxide assay method is illustrated in Figure 2. The rim 6 of the plug 3 fits snugly but movably within outer tube 2. Plug 3, whose inner core contains filter 4, fits immovable in the end of inner tube 1.
The bottom of tube 2 contains an excess of a support-bound FluoraBora, described above. Into tube 1 are introduced, in aqueous solution, excesses of all of the reactants, except the compound to be assayed, necessary to produce peroxide in the procedure being measured. A sample containing an unknown amount of the compound to be assayed, e.g., glucose, is introduced into tube 1, which is then pulled up to allow the solution, including any peroxidase produced, to pass downward through filter 4 to contact the support-bound FluoraBora. After the release of fluorophore into
solution has been completed, tube 1 is pushed down to allow the fluorophore in solution to pass upward through filter 4. The fluorescence of the solution, or of an extract of the solution, a measure of the compound being assayed in the sample, is measured with a fluorometer. Other Assays
The stable bond formed between FluoraBoras and supports containing hydroxyl groups and between FluoraBoras and certain other compounds, e.g., mucopolysaccharides, provides the basis for an assay for compounds having an affinity for boronic acids. The desired FluoraBora is contacted with an unknown amount of a compound to be assayed having an affinity for boronic acids. Another material having an affinity for boronic acids, e.g., one of the supports discussed above, is then added to the mixture. This second material binds with FluoraBora which did not complex with the compound being assayed. The amount of FluoraBora bound to this second material is inversely proportional to the amount of unknown present. Other Embodiments
Other embodiments are within the following claims. For example, many more compounds than are listed in the Tables are within the scope of the invention. Also, the assays can be varied in many conventional ways without departing from the inventive concept. For example, FluoraBoras can be used in standard displacement assays to measure compound having an affinity for boronic acids.
Table VI: Fluorescence of FluoraBoras in TAPSO vs ethyl acetate
TAPSO pH 7.4 ETHYL ACETATE
FBPA 1015μA/μmole 2363uA/umole
(370/953) (370/428)
FBI 8 . 8μA/μmole 61.3μA/μmole
(340/560) (340/510)
FBIII 436uA/μmole Quenched
( 330/410)
Table VII: Enhancement or inhibition of formula (1) compounds in serum albumin
Fluorescence enhancement
FBPA complexed with MOPSO 2.8
BICINE 2.4
BES 1.9
TAPS 1.7
TES 1.5
TAPSO 1.6
FBI complexed with MOPSO 6.8
BICINE 5.6
BES 5.0
TES 3.8
TAPS 3.2
TAPSO 2.4
FBIII complexed with MOPSO 0.33
BICINE 0.39
BES 0.40
TES 0.63
TAPS 0.68
TAPSO 0.75
Claims
Claims 1. A compound of the formula
wherein Rp1 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
2. The compound of claim 1, of the formula
wherein each R2 - R7, independently, is hydrogen, aryl, alkyl, heteroalkyl, heteroaryl, aralkyl, or a solubilizing group which is substantially ionized in water, provided that the compound contains at least one solubilizing group.
3. The compound of claim 1, of the formula
wherein each R2 - R5, independently, is hydrogen, aryl, alkyl, heteroalkyl, heteroaryl, aralkyl, or a solubilizing group which is substantially ionized in water, provided that the compound contains at least one solubilizing group.
4. The compound of claim 1, of the formula
wherein each R2 R5, independently, is hydrogen, aryl, alkyl, heteroalkyl, heteroaryl, aralkyl, or a solubilizing group which is substantially ionized in water, provided that the compound contains at least one solubilizing group, and each of n and m, independently, is 0, 2, or 3, provided that both cannot be 0, and provided that each R2 - R5 can be different in successive repeating units.
5. The compound of claim 2, of the formula
Rp2 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S,
Cg2 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
9. The compound of claim 8, of the formula
wherein
Sol is a solubilizing group which is substantially ionized in water,
A1 is alkyl, aryl, heteroaryl, heteroalkyl, or aralkyl, and each A2 - A7, independently, is hydrogen, aryl, alkyl, heteroalkyl, heteroaryl, aralkyl, or Rp2, provided that the compound contains at least one Rp2.
10. The compound of claim 8, of the formula
wherein Sol is a solubilizing group which is substantially ionized in water,
A1 is alkyl, aryl, heteroaryl, heteroalkyl, or aralkyl, and each A2 - A5, independently, is hydrogen, aryl, alkyl, heteroalkyl, heteroaryl, aralkyl, or Rp2, provided that the compound contains at least one Rp2.
11. The compound of claim 8, of the formula
wherein
Sol is a solubilizing group which is substantially ionized in water,
A1 is alkyl, aryl, heteroaryl, heteroalkyl, or aralkyl, each A2 - A5, independently, is hydrogen, aryl, alkyl, heteroalkyl, heteroaryl, aralkyl, or Rp2, provided that the compound contains at least one RP2, and each of p and q, independently, is 0, 2, or 3, provided that both cannot be 0, and provided that each A2 - A5 can be different in successive repeating units.
12. The compound of claim 9 , of the formula
13. The compound of claim 11 , of the formula
14. The compound of claim 1, said compound being chosen from the compounds listed in Table III herein.
15. The compound of claim 1, said compound being the reaction product of a compound listed in Table I herein and a compound listed in Table II herein.
16. The compound of claim 8, said compound being chosen from the compounds listed in Table IV herein.
17. A method of staining living cells comprising contacting said cells with a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S, Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
18. A method of staining a protein comprising contacting said protein with a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S,
Cg2 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
19. A method of staining a fabric or paper product comprising contacting said fabric or paper product with a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore or a chromophore, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
20. A method of brightening a fabric comprising contacting said fabric with a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore, each of X and Y, independently, is N, O, or S, Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
21. The method of any one of claims 17-20 where in said compound has the formula
22. A method of staining living cells comprising contacting said cells with a compound of the formula
Rp2 is a group which includes a reporter group comprising a fluorophore, a chromophore, an organometallic group, an antigen, or an isotopically-labelled group, each of X and Y, independently, is N, O, or S, Cg2 is a carrier group which includes solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
23. A method of staining a fabric or paper product comprising contacting said fabric or paper product with a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore or a chromophore, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
24. A method of brightening a fabric comprising contacting said fabric with a compound of the formula
Rp2 is a group which includes a reporter group comprising a fluorophore, each of X and Y, independently, is N, O, or S,
Cg2 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
26. A method of measuring, in aqueous solution, an unknown amount of a compound which participates in a chemical procedure which results in the production of peroxide comprising the steps of providing a reaction zone, introducing into said reaction zone excesses of all reactants, except said compound to be measured, participating in said chemical procedure, a sample containing an unknown amount of said compound to be measured, and a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore or a chromophore, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids, whereby said peroxide breaks the bond between Rp1 and B, thereby releasing Rp1-OH,
contacting said released Rp1-OH with a substance having a greater, affinity for Rp1-OH than for said compound of the formula
measuring the fluorescence or color intensity of said substance as a measure of the compound being measured.
27. The method of claim 26 wherein said substance is a water-immiscible organic solvent.
28. The method of claim 27 wherein said solvent is ethyl acetate.
29. The method of claim 26 wherein said substance is a water-miscible protein.
30. The method of claim 29 wherein said protein is serum albumin.
31. A method of measuring, in aqueous solution, an unknown amount of a compound which participates in an enzymatic procedure in which an enzyme acts on a substrate, said method comprising the steps of providing a reaction zone, introducing into said reaction zone excesses of all reactants, except said compound to be measured, participating in said enzymatic procedure, a sample containing an unknown amount of said compound to be measured, and a compound of the formula
Rp1 is a group which includes a reporter group comprising a fluorophore or a chromophore and, positioned between the boron atom and said chromophore or fluorophore, said substrate, each of X and Y, independently, is N,
O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids,
whereby said enzymatic procedure causes Rp1 to break at said substrate, releasing fluorophore and chromophore, contacting said fluorophore or chromophore with a substance having a greater affinity for the released fluorophore or chromophore than for said compound of the formula
, and
measuring the fluorescence or color intensity of said substance as a measure of the compound being measured.
32. The method of claim 31 wherein said substance is a water-immiscible organic solvent.
33. The method of claim 32 wherein said solvent is ethyl acetate.
34. The method of claim 31 wherein said substance is a water-miscible protein.
35. The method of claim 34 wherein said protein is serum albumin.
36. A method of measuring an antibody in a sample comprising providing red blood cells, contacting said red blood cells, in aqueous solution, with a compound of the formula
Rp1 is a group which includes a reporter group comprising a hapten capable of complexing with said antibody, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionized in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids, whereby the membranes of said red blood cells extract hapten-containing boronic acid, thereby becoming sensitized, contacting said sensitized red blood cells with said sample, together with complement capable of participating in the complexation of said hapten with said antibody, whereby said complexation occurs, causing the lysis of said red blood cells and the release of hemoglobin therefrom, and measuring said released hemoglobin as a measure of said antibody in said sample.
37. A method of measuring an antibody in a sample comprising providing red blood cells ghost, contacting said red blood cells ghost, in aqueous solution, with a compound of the formula
Rp1 is a group which includes a reporter group comprising a hapten capable of complexing with said antibody, and a reporter group comprising a fluorophore, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionizable in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids, whereby the membranes of said red blood cell ghosts extract hapten and fluorophore-containing boronic acid, thereby becoming sensitized, contacting said sensitized red blood cell ghosts with said sample, together with complement capable of participating in the complexation of said hapten with said antibody, whereby said complexation occurs, causing the lysis of said red blood cell ghosts and the release of fluorophore therefrom, and measuring released fluorescence as a measure of said antibody in said sample.
38. A method of improving the water solubility of a therapeutic agent of poor water solubility comprising chemically incorporating said therapeutic agent into a compound of the formula
Rp1 is a group which includes said therapeutic agent, each of X and Y, independently, is N, O, or S,
Cg1 is a carrier group which includes a solubilizing group which is substantially ionizable in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
39. A method of improving the water solubility of a therapeutic agent of poor water solubility comprising chemically incorporating said therapeutic agent into a compound of the formula
Rp2 is a group which includes said therapeutic agent, each of X and Y, independently, is N, O, or S,
Cg2 is a carrier group which includes a solubilizing group which is substantially ionizable in water, and r is a receptor group which, with X and Y, forms complexes with boronic acids.
40. The method of claim 38 or claim 39 wherein said therapeutic agent is diphenyl hydantoin or a derivative thereof.
41. The method of claim 38 or 39 wherein said therapeutic agent is carbamazapine or a derivative thereof.
42. A compound of the formula
wherein each of Ar1, and Ar2 is an aryl group, and Q is hydrogen or an alkyl group.
43. A compound of the formula
wherein, each of Ar1, and Ar2 is an aryl group, and Q is hydrogen or an alkyl group.
44. The compound of claim 42, of the formula
45. The compound of claim 43, of the formula
A compound of the formula
wherein
Re is a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group,
Ro is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl, and
Z' is a group linking Re and Ro.
wherein Y' is a group linking Re and Z'.
48. The compound of claim 46, said compound being chosen from the compounds listed in Table I herein.
49. The compound of claim 46 wherein Z' is NH, O, S, or COO.
50. The compound of claim 47 wherein
V being O or S, whereby said compound has the formula
52. A method of staining living cells comprising contacting said cells with a water-soluble, non-toxic compound of the formula
Re is a reporter group comprising a fluorophore, a chromophore, an organometallic group, an antigen, or an isotopically-labelled group,
Ro is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl, and Z' is a group linking Re and Ro.
53. The method of claim 52 wherein said compound has the formula
54. A method of staining the surfaces of eyes comprising contacting said eyes or living cells with a water-soluble, non-toxic compound of the formula
Ro is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl, and
Z' is a group linking Re and Ro.
56. A method of measuring, in a sample, a compound having an affinity for boronic acids comprising contacting said sample with a compound of the formula
Re is a reporter group comprising a fluorophore, a chromophore, an organometallic group, a therapeutic agent, an antigen, or an isotopically-labelled group,
Ro is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl, and
Z' is a group linking Re and Ro, thereby to form a mixture, contacting said mixture with a material having an affinity for boronic acids, and measuring the amount of compound of the aforesaid formula bound to said material, said amount being inversely proportional to the amount of said compound having an affinity for boronic acids present in said sample.
57. A composition comprising an organic, polymeric, water-insoluble support having hydroxyl groups capable of complexing with boronic acids, and bound to said support, a compound of the formula
wherein
Re is a reporter group comprising a fluorophore, a chromophore, an antigen, or an isotopically-labelled group,
Ro is aryl, alkyl, heteroalkyl, heteroaryl, or aralkyl, and
Z ' is a group linking Re and Ro.
58. The composition of claim 57 wherein said support is hydrophobic fibrous polyethylene containing attached polyvinyl alcohol.
59. A method for assaying, in aqueous solution, a compound which participates in a chemical procedure which results in the production of peroxide comprising the steps of providing a reaction zone, introducing into said reaction zone excesses of all reactants, except said compound to be assayed, a sample containing an unknown amount of said compound to be assayed, and the composition of claim 57, wherein Re comprises a fluorophore, whereby fluorophore is released into solution, and measuring released fluorescence as a measure of said compound being assayed.
60. The method of claim 59, further comprising the step of separating said released fluorophore from said support.
61. The method of claim 60 wherein said separating is carried out by filtering.
62. The method of claim 60 wherein said separating is carried out by centrifugation.
63. The method of claim 60 wherein said separating is carried out by dissolving said fluorophore compound in an organic, water- immiscible solvent.
64. The method of claim 59 wherein said compound to be assayed is glucose.
65. Apparatus for assaying, in aqueous solution, a compound which participates in a chemical procedure which results in the production of peroxide comprising the composition of claim 57, wherein Re comprises a fluorophore means for providing a reaction zone for the production of said peroxide, and means for contacting said peroxide with said composition of claim 57, thereby to release fluorophore into solution.
66. The apparatus of claim 65, further comprising all reactants, except said compound to be assayed, which participate in said production of peroxide.
67. The apparatus of claim 65, further comprising means for maintaining the pH of said reaction zone in the range of about 8 to 9, and means for separating said dissolved fluorophore from said insoluble support.
68. The apparatus of claim 65 wherein said compound to be assayed is glucose.
69. The apparatus of claim 67 wherein said separating means comprises filtering means.
70. The apparatus of claim 67 wherein said separating means comprises an organic, water-immiscible solvent capable of dissolving saidfluorophore.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1982/000725 WO1983004255A1 (en) | 1982-05-26 | 1982-05-26 | Reporter compounds |
EP82902137A EP0110879A1 (en) | 1982-05-26 | 1982-05-26 | Reporter compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1982/000725 WO1983004255A1 (en) | 1982-05-26 | 1982-05-26 | Reporter compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1983004255A1 true WO1983004255A1 (en) | 1983-12-08 |
Family
ID=22168016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1982/000725 WO1983004255A1 (en) | 1982-05-26 | 1982-05-26 | Reporter compounds |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0110879A1 (en) |
WO (1) | WO1983004255A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0282448A2 (en) * | 1987-03-05 | 1988-09-14 | Ciba-Geigy Ag | Pyrazoline compounds |
EP0414730A1 (en) * | 1988-03-31 | 1991-03-06 | Randell L. Mills | Luminide and macroluminide class of pharmaceuticals |
WO1991004488A1 (en) * | 1989-09-21 | 1991-04-04 | Russell Anthony P | Method and means for detecting polyhydroxyl compounds |
EP0424168A1 (en) * | 1989-10-19 | 1991-04-24 | Nippon Oil And Fats Company, Limited | Polymer complexes of a sugar response type |
WO2002099077A2 (en) * | 2001-06-06 | 2002-12-12 | Proteologics, Inc. | Methods and compositions related to tagging of membrane surface proteins |
US7317000B2 (en) | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
FR2966153A1 (en) * | 2010-10-19 | 2012-04-20 | Commissariat Energie Atomique | USE OF CYCLIC AZABORONATES AS SENSITIVE MATERIALS IN SENSORS FOR DETECTING THE PRESENCE OF PEROXIDES IN A GASEOUS MEDIUM |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB790090A (en) * | 1952-12-02 | 1958-02-05 | Bataafsche Petroleum | Cyclic boron compounds |
US3038926A (en) * | 1958-09-17 | 1962-06-12 | Roussel Uclaf | Organic diol aryl boronates |
US3131208A (en) * | 1962-05-07 | 1964-04-28 | United States Borax Chem | Glycol monoborates |
-
1982
- 1982-05-26 WO PCT/US1982/000725 patent/WO1983004255A1/en unknown
- 1982-05-26 EP EP82902137A patent/EP0110879A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB790090A (en) * | 1952-12-02 | 1958-02-05 | Bataafsche Petroleum | Cyclic boron compounds |
US3038926A (en) * | 1958-09-17 | 1962-06-12 | Roussel Uclaf | Organic diol aryl boronates |
US3131208A (en) * | 1962-05-07 | 1964-04-28 | United States Borax Chem | Glycol monoborates |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS Volume 88, No. 17 issued 24 April 1978, (Columbus, Ohio, U.S.A.) A.G. SMITH et al, 'Gas Chromotography Chemical Ionization Mass Spectrometry of Prostaglandin Fa Cyclic Bornate Derivatives' see page 459, column 1, the Abstract No. 120142m Biomed Spectom. 1977, 4(4) 258-64 (Eng). (section 22) * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0282448A3 (en) * | 1987-03-05 | 1988-09-21 | Ciba-Geigy Ag | Pyrazoline compounds |
EP0282448A2 (en) * | 1987-03-05 | 1988-09-14 | Ciba-Geigy Ag | Pyrazoline compounds |
EP0414730A4 (en) * | 1988-03-31 | 1993-06-16 | Randell L. Mills | Luminide and macroluminide class of pharmaceuticals |
EP0414730A1 (en) * | 1988-03-31 | 1991-03-06 | Randell L. Mills | Luminide and macroluminide class of pharmaceuticals |
AU650425B2 (en) * | 1989-09-21 | 1994-06-23 | Anthony P. Russell | Method and means for detecting polyhydroxyl compounds |
WO1991004488A1 (en) * | 1989-09-21 | 1991-04-04 | Russell Anthony P | Method and means for detecting polyhydroxyl compounds |
EP0424168A1 (en) * | 1989-10-19 | 1991-04-24 | Nippon Oil And Fats Company, Limited | Polymer complexes of a sugar response type |
US5478575A (en) * | 1989-10-19 | 1995-12-26 | Nippon Oil & Fats Co., Ltd. | Polymers having benzeneboronic acid groups and insulin complexes of same of a sugar response type |
WO2002099077A2 (en) * | 2001-06-06 | 2002-12-12 | Proteologics, Inc. | Methods and compositions related to tagging of membrane surface proteins |
WO2002099077A3 (en) * | 2001-06-06 | 2003-11-13 | Proteologics Inc | Methods and compositions related to tagging of membrane surface proteins |
US7317000B2 (en) | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
FR2966153A1 (en) * | 2010-10-19 | 2012-04-20 | Commissariat Energie Atomique | USE OF CYCLIC AZABORONATES AS SENSITIVE MATERIALS IN SENSORS FOR DETECTING THE PRESENCE OF PEROXIDES IN A GASEOUS MEDIUM |
WO2012052399A1 (en) * | 2010-10-19 | 2012-04-26 | Commissariat à l'énergie atomique et aux énergies alternatives | Use of cyclic azaboronates as sensitive materials in sensors intended to detect the presence of peroxides in a gaseous environment |
US9194853B2 (en) | 2010-10-19 | 2015-11-24 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Use of cyclic azaboronates as sensitive materials in sensors for detecting the presence of peroxides in a gaseous environment |
Also Published As
Publication number | Publication date |
---|---|
EP0110879A1 (en) | 1984-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4496722A (en) | Reporter compounds | |
US4659817A (en) | Reporter compounds containing boron | |
US11740233B2 (en) | Antibody-nanoparticle conjugates and methods for making and using such conjugates | |
DE3788356T2 (en) | MONOMER PHTHALOCYANIN REAGENTS. | |
Thompson et al. | Fluorescent zinc indicators for neurobiology | |
CA1337754C (en) | Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents | |
US5135717A (en) | Tetrabenztriazaporphyrin reagents and kits containing the same | |
US8389223B2 (en) | Probes for anionic cell surface detection | |
CN114478473B (en) | Synthesis and application of leucine aminopeptidase chemiluminescence detection reagent | |
CN112500386B (en) | Near-infrared HClO fluorescent probe based on piroctone olamine, preparation and application thereof | |
CN113956265B (en) | Near-infrared molecular probe based on malondialdehyde response, preparation method and application thereof | |
EP0297303B1 (en) | Fluorophores for encapsulation into liposomes | |
US8968997B2 (en) | Benzoxazole-based fluorescent metal ion indicators | |
US9920020B2 (en) | Using squaraine dyes as near infrared fluorescent sensors for protein detection | |
WO1983004255A1 (en) | Reporter compounds | |
US11045559B2 (en) | Reactive fluorogenic compound and nanocomposite for sensing hydrogen sulfide comprising the same | |
EP0277139A1 (en) | 7-amino-4-methyl-coumarin-3-carboxyalkyl derivatives and fluorescent conjugates thereof. | |
CN108699091B (en) | pH-responsive fluorescent compound, composition for detecting mitophagy using same, and method for detecting mitophagy in cell | |
CN112694469B (en) | Pyrrosinyl-based HOCl fluorescent probe, and preparation method and application thereof | |
CN103435625A (en) | Red light emission rhodamine-based ionic fluorescent probe and application thereof | |
CA2266405A1 (en) | Immunohistochemical staining composition | |
CN108610270B (en) | Bicyano diphenylethylene type two-photon fluorescent solvent chromogenic water-soluble probe and synthetic method and application thereof | |
US4970074A (en) | Fluorophores for encapsulation into liposomes | |
IE870866L (en) | Rainbow text device (composition for visual determination of¹analyte in fluids). | |
Dubicki | Insights Towards Optimizing Palladium-Catalyzed Bioorthogonal Reactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): DE GB JP |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB LU NL SE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |